Specificity of cyclin D1 for androgen receptor regulation

Cancer Research

Volumn 63, Issue 16, 2003, Pages 4903-4913

  Petre Draviam, Christin E ^a   Cook, Stephen L ^a   Burd, Craig J ^a   Marshall, Thomas W ^a   Wetherill, Yelena B ^a   Knudsen, Karen E ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; COMPLEMENTARY DNA; CYCLIN D1; ESTRADIOL; PROGESTERONE;

ANIMAL CELL; ARTICLE; CANCER CELL CULTURE; CANCER HORMONE THERAPY; DNA BINDING; GENE REPRESSION; GENETIC POLYMORPHISM; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; HORMONE ACTION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; LIGAND BINDING; MALE GENITAL TRACT CANCER; MOUSE MAMMARY TUMOR ONCOVIRUS; NONHUMAN; PLASMID; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; PROSTATE DISEASE; PROTEIN ANALYSIS; PROTEIN PHOSPHORYLATION; REPORTER GENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADENOCARCINOMA; BINDING SITES; CELL LINE; CYCLIN D1; DNA; HUMANS; MALE; NEOPLASMS, HORMONE-DEPENDENT; PHOSPHORYLATION; PROMOTER REGIONS (GENETICS); PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; REPRESSOR PROTEINS; TRANS-ACTIVATION (GENETICS);

EID: 0041438474     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (66)

1. Denmeade, S. R., and Isaacs, J. T. A history of prostate cancer treatment. Nat. Rev. Cancer, 2: 389-396, 2002.
2. Feldman, B. J., and Feldman, D. The development of androgen-independent prostate cancer. Nat. Rev. Cancer, 1: 34-45, 2001.
3. Taplin, M. E., and Ho, S. M. Clinical review 134: the endocrinology of prostate cancer. J. Clin. Endocrinol. Metab., 86: 3467-3477, 2001.
4. Denmeade, S. R., Lin, X. S., and Isaacs, J. T. Role of programmed (apoptotic) cell death during the progression and therapy for prostate cancer. Prostate, 28: 251-265, 1996.
5. Brinkmann, A. O., Blok, L. J., de Ruiter, P. E., Doesburg, P., Steketee, K., Berrevoets, C. A., and Trapman, J. Mechanisms of androgen receptor activation and function. J. Steroid Biochem. Mol. Biol., 69: 307-313, 1999.
6. Chang, C. S., Kokontis, J., and Liao, S. T. Molecular cloning of human and rat complementary DNA encoding androgen receptors. Science (Wash. DC), 240: 324-326, 1988.
7. Jenster, G., van der Korput, J. A., Trapman, J., and Brinkmann, A. O. Functional domains of the human androgen receptor. J. Steroid Biochem. Mol. Biol., 41: 671-675, 1992.
8. 2-terminal domain. J. Biol. Chem., 274: 37219-37225, 1999.
9. Marivoet, S., Van Dijck, P., Verhoeven, G., and Heyns, W. Interaction of the 90-kDa heat shock protein with native and in vitro translated androgen receptor and receptor fragments. Mol. Cell. Endocrinol., 88: 165-174, 1992.
10. Roy, A. K., Tyagi, R. K., Song, C. S., Lavrovsky, Y., Ahn, S. C., Oh, T. S., and Chatterjee, B. Androgen receptor: structural domains and functional dynamics after ligand-receptor interaction. Ann. N. Y. Acad. Sci., 949: 44-57, 2001.
11. Trapman, J., and Brinkmann, A. O. The androgen receptor in prostate cancer. Pathol. Res. Pract., 192: 752-760, 1996.
12. Nash, A. F., and Melezinek, I. The role of prostate specific antigen measurement in the detection and management of prostate cancer. Endocr. Relat. Cancer, 7: 37-51, 2000.
13. Riegman, P. H., Vlietstra, R. J., van der Korput, J. A., Brinkmann, A. O., and Trapman, J. The promoter of the prostate-specific antigen gene contains a functional androgen responsive element. Mol. Endocrinol., 5: 1921-1930, 1991.
14. Culig, Z., Klocker, H., Bartsch, G., and Hobisch, A. Androgen receptors in prostate cancer. Endocr. Relat. Cancer, 9: 155-170, 2002.
15. Hobisch, A., Eder, I. E., Putz, T., Horninger, W., Bartsch, G., Klocker, H., and Culig, Z. Interleukin-6 regulates prostate-specific protein expression in prostate carcinoma cells by activation of the androgen receptor. Cancer Res., 58: 4640-4645, 1998.
16. Culig, Z., Hobisch, A., Cronauer, M. V., Radmayr, C., Trapman, J., Hittmair, A., Bartsch, G., and Klocker, H. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor I, keratinocyte growth factor, and epidermal growth factor. Cancer Res., 54: 5474-5478, 1994.
17. Balk, S. P. Androgen receptor as a target in androgen-independent prostate cancer. Urology, 60: 132-138; discussion 138-139, 2002.
18. Knudsen, K. E., Cavenee, W. K., and Arden, K. C. D-Type cyclins complex with the androgen receptor and inhibit its transcriptional transactivation ability. Cancer Res., 59: 2297-2301, 1999.
19. Petre, C. E., Wetherill, Y. B., Danielsen, M., and Knudsen, K. E. Cyclin D1: mechanism and consequence of androgen receptor co-repressor activity. J. Biol. Chem., 277: 2207-2215, 2002.
20. Neuman, E., Ladha, M. H., Lin, N., Upton, T. M., Miller, S. J., DiRenzo, J., Pestell, R. G., Hinds, P. W., Dowdy, S. F., Brown, M., and Ewen, M. E. Cyclin D1 stimulation of estrogen receptor transcriptional activity independent of cdk4. Mol. Cell. Biol., 17: 5338-5347, 1997.
21. Zwijsen, R. M., Buckle, R. S., Hijmans, E. M., Loomans, C. J., and Bernards, R. Ligand-independent recruitment of steroid receptor coactivators to estrogen receptor by cyclin D1. Genes Dev., 12: 3488-3498, 1998.
22. McMahon, C., Suthiphongchai, T., DiRenzo, J., and Ewen, M. E. P/CAF associates with cyclin D1 and potentiates its activation of the estrogen receptor. Proc. Natl. Acad. Sci. USA, 96: 5382-5387, 1999.
23. Coqueret, O. Linking cyclins to transcriptional control. Gene (Amst.), 299: 35-55, 2002.
24. Fribourg, A. F., Knudsen, K. E., Strobeck, M. W., Lindhorst, C. M., and Knudsen, E. S. Differential requirements for ras and the retinoblastoma tumor suppressor protein in the androgen dependence of prostatic adenocarcinoma cells. Cell Growth Differ., 11: 361-372, 2000.
25. Hinds, P. W., Dowdy, S. F., Eaton, E. N., Arnold, A., and Weinberg, R. A. Function of a human cyclin gene as an oncogene. Proc. Natl. Acad. Sci. USA, 91: 709-713, 1994.
26. Reutens, A. T., Fu, M., Wang, C., Albanese, C., McPhaul, M. J., Sun, Z., Balk, S. P., Janne, O. A., Palvimo, J. J., and Pestell, R. G. Cyclin D1 binds the androgen receptor and regulates hormone-dependent signaling in a p300/CBP-associated factor (P/CAF)-dependent manner. Mol. Endocrinol., 15: 797-811, 2001.
27. 1-S transition. J. Biol. Chem., 277: 29719-29729, 2002.
28. Sramkoski, R. M., Pretlow, T. G., II, Giaconia, J. M., Pretlow, T. P., Schwartz, S., Sy, M. S., Marengo, S. R., Rhim, J. S., Zhang, D., and Jacobberger, J. W. A new human prostate carcinoma cell line, 22Rv1. In Vitro Cell Dev. Biol. Anim., 35: 403-409, 1999.
29. Wetherill, Y. B., Petre, C. E., Monk, K. R., Puga, A., and Knudsen, K. E. The xenoestrogen bisphenol A induces inappropriate androgen receptor activation and mitogenesis in prostatic adenocarcinoma cells. Mol. Cancer Ther., 1: 515-524, 2002.
30. Sadar, M. D. Androgen-independent induction of prostate-specific antigen gene expression via cross-talk between the androgen receptor and protein kinase A signal transduction pathways. J. Biol. Chem., 274: 7777-7783, 1999.
31. Fenton, M. A., Shuster, T. D., Fertig, A. M., Taplin, M. E., Kolvenbag, G., Bubley, G. J., and Balk, S. P. Functional characterization of mutant androgen receptors from androgen-independent prostate cancer. Clin. Cancer Res., 3: 1383-1388, 1997.
32. Palvimo, J. J., Kallio, P. J., Ikonen, T., Mehto, M., and Janne, O. A. Dominant negative regulation of trans-activation by the rat androgen receptor: roles of the N-terminal domain and heterodimer formation. Mol. Endocrinol., 7: 1399-1407, 1993.
33. Stenoien, D. L., Cummings, C. J., Adams, H. P., Mancini, M. G., Patel, K., DeMartino, G. N., Marcelli, M., Weigel, N. L., and Mancini, M. A. Polyglutamine-expanded androgen receptors form aggregates that sequester heat shock proteins, proteasome components and SRC-1, and are suppressed by the HDJ-2 chaperone. Hum. Mol. Genet., 8: 731-741, 1999.
34. Zhou, Z. X., Kemppainen, J. A., and Wilson, E. M. Identification of three proline-directed phosphorylation sites in the human androgen receptor. Mol. Endocdnol., 9: 605-615, 1995.
35. Marshall, T. W., Link, K. A., Petre-Draviam, C. E., and Knudsen, K. E. Differential requirement of SWI/SNF for androgen receptor activity. J. Biol. Chem., in press, 2003.
36. Chen, C., and Okayama, H. High-efficiency transformation of mammalian cells by plasmid DNA. Mol. Cell. Biol., 7: 2745-2752, 1987.
37. Holter, E., Kotaja, N., Makela, S., Strauss, L., Kietz, S., Janne, O. A., Gustafsson, J. A., Palvimo, J. J., and Treuter, E. Inhibition of androgen receptor (AR) function by the reproductive orphan nuclear receptor DAX-1. Mol. Endocrinol., 16: 515-528, 2002.
38. Kaighn, M. E., Narayan, K. S., Ohnuki, Y., Lechner, J. F., and Jones, L. W. Establishment and characterization of a human prostatic carcinoma cell line (PC-3). Investig. Urol. (Berl.), 17: 16-23, 1979.
39. van Bokhoven, A., Varella-Garcia, M., Korch, C., and Miller, G. J. TSU-Pr1 and JCA-1 cells are derivatives of T24 bladder carcinoma cells and are not of prostatic origin. Cancer Res., 61: 6340-6344, 2001.
40. Ando, S., De Amicis, F., Rago, V., Carpino, A., Maggiolini, M., Panno, M., and Lanzino, M. Breast cancer: from estrogen to androgen receptor. Mol. Cell. Endocrinol., 193: 121-128, 2002.
41. Bentel, J. M., Birrell, S. N., Pickering, M. A., Holds, D. J., Horsfall, D. J., and Tilley, W. D. Androgen receptor agonist activity of the synthetic progestin, medroxyprogesterone acetate, in human breast cancer cells. Mol. Cell. Endocrinol., 154: 11-20, 1999.
42. Yamamoto, A., Hashimoto, Y., Kohri, K., Ogata, E., Kato, S., Ikeda, K., and Nakanishi, M. Cyclin E as a coactivator of the androgen receptor. J. Cell Biol., 150: 873-880, 2000.
43. Claessens, F., Verrijdt, G., Schoenmakers, E., Haelens, A., Peeters, B., Verhoeven, G., and Rombauts, W. Selective DNA binding by the androgen receptor as a mechanism for hormone-specific gene regulation. J. Steroid Biochem. Mol. Biol., 76: 23-30, 2001.
44. Kotaja, N., Aittomaki, S., Silvennoinen, O., Palvimo, J. J., and Janne, O. A. ARIP3 (androgen receptor-interacting protein 3) and other PIAS (protein inhibitor of activated STAT) proteins differ in their ability to modulate steroid receptor-dependent transcriptional activation. Mol. Endocrinol., 14: 1986-2000, 2000.
45. Gioeli, D., Ficarro, S. B., Kwiek, J. J., Aaronson, D., Hancock, M., Catling, A. D., Whit, F. M., Christian, R. E., Settlage, R. E., Shabanowitz, J., Hunt, D. F., and Weber, M. J. Androgen receptor phosphorylation. Regulation and identification of the phosphorylation sites. J. Biol. Chem., 277: 29304-29314, 2002.
46. Giovannucci, E., Stampfer, M. J., Krithivas, K., Brown, M., Dahl, D., Brufsky, A., Talcott, J., Hennekens, C. H., and Kantoff, P. W. The CAG repeat within the androgen receptor gene and its relationship to prostate cancer. Proc. Natl. Acad. Sci. USA, 94: 3320-3323, 1997.
47. Giovannucci, E., Platz, E. A., Stampfer, M. J., Chan, A., Krithivas, K., Kawachi, I., Willett, W. C., and Kantoff, P. W. The CAG repeat within the androgen receptor gene and benign prostatic hyperplasia. Urology, 53: 121-125, 1999.
48. Hakimi, J. M., Schoenberg, M. P., Rondinelli, R. H., Piantadosi, S., and Barrack, E. R. Androgen receptor variants with short glutamine or glycine repeats may identify unique subpopulations of men with prostate cancer. Clin. Cancer Res., 3: 1599-1608, 1997.
49. Chamberlain, N. L., Driver, E. D., and Miesfeld, R. L. The length and location of CAG trinucleotide repeats in the androgen receptor N-terminal domain affect transactivation function. Nucleic Acids Res., 22: 3181-3186, 1994.
50. Beilin, J., Ball, E. M., Favaloro, J. M., and Zajac, J. D. Effect of the androgen receptor CAG repeat polymorphism on transcriptional activity: specificity in prostate and non-prostate cell lines. J. Mol. Endocrinol., 25: 85-96, 2000.
51. Taplin, M. E., Bubley, G. J., Ko, Y. J., Small, E. J., Upton, M., Rajeshkumar, B., and Balk, S. P. Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist. Cancer Res., 59: 2511-2515, 1999.
52. Nichols, M., Rientjes, J. M., and Stewart, A. F. Different positioning of the ligand-binding domain helix 12 and the F domain of the estrogen receptor accounts for functional differences between agonists and antagonists. EMBO J., 17: 765-773, 1998.
53. Hsiao, P. W., Thin, T. H., Lin, D. L., and Chang, C. Differential regulation of testosterone versus 5α-dihydrotestosterone by selective androgen response elements. Mol. Cell. Biochem., 206: 169-175, 2000.
54. Deslypere, J. P., Young, M., Wilson, J. D., and McPhaul, M. J. Testosterone and 5α-dihydrotestosterone interact differently with the androgen receptor to enhance transcription of the MMTV-CAT reporter gene. Mol. Cell. Endocrinol., 88: 15-22, 1992.
55. Smith, P. C., Hobisch, A., Lin, D. L., Culig, Z., and Keller, E. T. Interleukin-6 and prostate cancer progression. Cytokine Growth Factor Rev., 12: 33-40, 2001.
56. Ueda, T., Bruchovsky, N., and Sadar, M. D. Activation of the androgen receptor N-terminal domain by interleukin-6 via MAPK and STAT3 signal transduction pathways. J. Biol. Chem., 277: 7076-7085, 2002.
57. Giri, D., Ozen, M., and Ittmann, M. Interleukin-6 is an autocrine growth factor in human prostate cancer. Am. J. Pathol., 159: 2159-2165, 2001.
58. Russell, P. J., Bennett, S., and Stricker, P. Growth factor involvement in progression of prostate cancer. Clin. Chem., 44: 705-723, 1998.
59. Drachenberg, D. E., Elgamal, A. A., Rowbotham, R., Peterson, M., and Murphy, G. P. Circulating levels of interleukin-6 in patients with hormone refractory prostate cancer. Prostate, 41: 127-133, 1999.
60. Ueda, T., Mawji, N. R., Bruchovsky, N., and Sadar, M. D. Ligand-independent activation of the androgen receptor by interleukin-6 and the role of steroid receptor coactivator-1 in prostate cancer cells. J. Biol. Chem., 277: 38087-38094, 2002.
61. 2- and COOH-terminal interaction. J. Biol. Chem., 277: 25631-25639, 2002.
62. Brookes, D. E., Zandvliet, D., Watt, F., Russell, P, J., and Molloy, P. L. Relative activity and specificity of promoters from prostate-expressed genes. Prostate, 35: 18-26, 1998.
63. La Spada, A. R., Wilson, E. M., Lubahn, D. B., Harding, A. E., and Fischbeck, K. H. Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy. Nature (Lond.), 352: 77-79, 1991.
64. Orr, H. T., Chung, M. Y., Banfi, S., Kwiatkowski, T. J., Jr., Servadio, A., Beaudet, A. L., McCall, A. E., Duvick, L. A., Ranum, L. P., and Zoghbi, H. Y. Expansion of an unstable trinucleotide CAG repeat in spinocerebellar ataxia type 1. Nat. Genet., 4: 221-226, 1993.
65. Buchanan, G., Greenberg, N. M., Scher, H. I., Harris, J. M., Marshall, V. R., and Tilley, W. D. Collocation of androgen receptor gene mutations in prostate cancer. Clin. Cancer Res., 7: 1273-1281, 2001.
66. Matias, P. M., Donner, P., Coelho, R., Thomaz, M., Peixoto, C., Macedo, S., Otto, N., Joschko, S., Scholz, P., Wegg, A., Basler, S., Schafer, M., Egner, U., and Carrondo, M. A. Structural evidence for ligand specificity in the binding domain of the human androgen receptor. Implications for pathogenic gene mutations. J. Biol. Chem., 275: 26164-26171, 2000.